About
Technology
Issues
FAQ
Links
Official Page
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.